Whistleblower claims HHS failed to protect workers from coronavirus

More than a dozen HHS workers sent to receive American evacuees from Wuhan, China––where the novel coronavirus originated––without proper training and protective gear, according to a whistleblower complaint reported by The Washington Post.

The whistleblower alleged she was unfairly reassigned after raising concerns about the safety of the workers, who were not tested for coronavirus, dubbed COVID-19, and did not show symptoms of infection. Her complaint was filed Feb. 26 with independent watchdog agency, the Office of the Special Counsel, The Post reported.

The complaint also alleges the workers were exposed to the virus and appropriate steps were not taken to protect them. Specifically, the workers had face-to-face contact with returning passengers from China, handing out identification ribbons and room keys. The workers were alongside CDC workers who were fully outfitted in hazmat attire and protective gear in some instances. According to the whistleblower, HHS also broke protocol when it came to what kinds of employees responded to the health emergency.

The whistleblower’s allegations comes as the first patient to be infected with COVID-19 who did not travel or have known contact with an infected person was confirmed in California.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.